Miya B. Hugaboom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miya B. Hugaboom has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- David A. Braun
Yale School of Medicine, New Haven, CT, USA
63 shared publications - Kelly Street
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California
62 shared publications - Catherine J. Wu
Dana-Farber Cancer Institute
61 shared publications - David F. McDermott
Harvard Medical School, Boston, Massachusetts
61 shared publications - Destiny J. West
Brigham and Women’s Hospital 1 Department of Pathology Boston, Massachusetts
61 shared publications - Elizabeth R. Plimack
Fox Chase Cancer Center
61 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Molecular subtypes by primary/metastatic status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Molecular subtypes by primary/metastatic status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Analysis of tertiary lymphoid structure enrichment in responders, continued from Fig 2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Analysis of tertiary lymphoid structure enrichment in responders, continued from Fig 2.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
ZNF683+ SLAMF7+ Exhausted CD8+ T cell GES validation in external clinical cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
ZNF683+ SLAMF7+ Exhausted CD8+ T cell GES validation in external clinical cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Patient and sample characteristics of scRNA/scTCR sequencing cohort, related to Figure 1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Patient and sample characteristics of scRNA/scTCR sequencing cohort, related to Figure 1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Patient and sample characteristics of bulk RNA sequencing cohort, related to Figure 1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Patient and sample characteristics of bulk RNA sequencing cohort, related to Figure 1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
RNA expression (normalized expression matrix), related to Figure 1.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
RNA expression (normalized expression matrix), related to Figure 1.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of myeloid cells, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other myeloid clusters.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Differential gene expression analysis, including top 1,000 differentially expressed genes for each cluster (compared with all other clusters) for graph-based clustering of myeloid cells, related to Figure 4. Positive log fold-change (per cluster) indicates upregulation in cluster of interest compared to all other myeloid clusters.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Functional validation of SLAMF7 activation on T cell functions and flow cytometry gating strategies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
Functional validation of SLAMF7 activation on T cell functions and flow cytometry gating strategies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
ZNF683+ SLAMF7+ Exhausted CD8+ T cell and TLS GES integration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
ZNF683+ SLAMF7+ Exhausted CD8+ T cell and TLS GES integration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
TCR specificity in advanced renal cell carcinoma.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma
TCR specificity in advanced renal cell carcinoma.